证券代码：002584 证券简称：西陇科学 西陇科学股份有限公司 2022 年度业绩说明会 投资者活动记录表 编号：2023-001 | --- | --- | |--------------|----------------------------| | | □分析师会议 | | | □媒体采访 √业绩说明会 | | 投资者关系活 | | | | □新闻发布会 □路演活动 | | 动类别 | | | | □现场参观 □电话会议 | | | （请文字说明其他活动内容） | 参与单位名称 及人员姓名 西陇科学2022年度业绩说明会采用网络远程方式进行，面向全体投资者 时间 2023 年 5 月 11 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏 目 主持人：西陇科学 董事长, 总裁：黄少群 公司接待人员 独立董事：曾幸荣 姓名 副总裁、财务总监：王庆东 副总裁、董事会秘书：宗岩 1.公司的会计不够专业，公司有没有认真按照会计流程工作？出错后可 有采取什么补救措施？ 投资者关系活 动主要内容介 答：尊敬的投资者您好，公司一直重视财务管理 ...

Revenue and Profit - The company's revenue for Q1 2023 was ¥1,937,787,670.11, representing a 41.37% increase compared to ¥1,370,689,076.75 in the same period last year[5] - Net profit attributable to shareholders decreased by 87.27% to ¥10,032,938.44 from ¥78,789,802.66 year-on-year[5] - Basic and diluted earnings per share dropped by 84.62% to ¥0.02 from ¥0.13 in the same period last year[5] - The net profit for Q1 2023 was CNY 10,263,465.80, a significant decrease from CNY 78,992,204.84 in Q1 2022, representing a decline of approximately 87%[21] - The total comprehensive income for Q1 2023 was CNY 10,209,000.26, compared to CNY 78,972,725.68 in Q1 2022, indicating a decrease of approximately 87%[22] Cash Flow and Operating Activities - The net cash flow from operating activities was negative at -¥13,769,371.14, a decline of 208.42% compared to ¥12,699,955.54 in the previous year[11] - The cash flow from operating activities showed a net outflow of CNY 13,769,371.14, contrasting with a net inflow of CNY 12,699,955.54 in the same period last year[23] - The net cash flow from financing activities was -CNY 181,091,623.31, compared to -CNY 194,630,992.88 in the same period last year[23] Assets and Liabilities - Total assets increased by 1.61% to ¥5,057,362,009.89 from ¥4,977,416,163.23 at the end of the previous year[5] - The total liabilities increased to CNY 2,731,999,097.66 from CNY 2,661,074,952.66, indicating a rise of 2.6%[18] - The cash and cash equivalents at the end of the first quarter were CNY 746,942,400.01, up from CNY 691,010,308.36 at the beginning of the year, representing an increase of 8.1%[16] - The inventory balance increased to CNY 628,233,968.66 from CNY 508,198,483.15, marking a significant rise of 23.6%[16] - The company experienced a 35.08% decrease in trading financial assets, dropping to ¥194,525,348.36 from ¥299,652,718.51 due to bank wealth management products maturing[8] Costs and Expenses - The company reported a significant increase in main business costs, which rose by 46.57% to ¥1,821,756,346.94 due to higher demand for specialized chemical products[10] - The total operating costs for the first quarter of 2023 were CNY 1,921,849,607.63, up 42.4% from CNY 1,347,511,178.74 in the previous year[19] - The company incurred a total operating profit of CNY 10,843,265.98, a decrease from CNY 88,433,285.73 in the previous year[21] - The company’s research and development expenses for the first quarter were CNY 13,057,237.98, down 19.0% from CNY 16,110,350.98 in the previous year[19] Investment and Financing - Investment income plummeted by 101.31% to -¥951,681.56 from ¥72,607,438.26 in the previous year, primarily impacting net profit[10] - The total cash inflow from investment activities was CNY 300,346,508.14, down from CNY 389,951,398.69 in Q1 2022[23] - Short-term borrowings increased by 32.28% to ¥992,194,390.15 from ¥750,092,603.45, indicating a rise in financing needs[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 68,218, with no preferred shareholders[13] - The net profit attributable to the parent company for the first quarter of 2023 was not explicitly stated but can be inferred from the increase in revenue and costs[19]

Financial Performance - The company reported a revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[12]. - The net profit attributable to shareholders was RMB 200 million, up 10% compared to the previous year[12]. - The company's operating revenue for 2022 was ¥6,183,208,812.19, a decrease of 14.93% compared to ¥6,837,667,633.82 in 2021[17]. - The net profit attributable to shareholders was ¥88,047,360.97, representing a decline of 52.93% from ¥203,877,034.92 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥7,608,961.07, down 83.00% from ¥57,597,437.75 in 2021[17]. - The net cash flow from operating activities was -¥190,882,683.70, a significant decrease of 151.18% compared to ¥346,617,647.91 in 2021[17]. - The company reported a significant decline in revenue from the medical industry, down 90.44% to ¥18,174,261.12[61]. - The total operating revenue for the reporting period reached ¥6,183,208,812.19, representing a year-on-year increase of 14.93% compared to ¥5,379,903,593.41 in 2021[61]. Investment and R&D - The company plans to invest RMB 300 million in R&D for new product development in the upcoming year, focusing on electronic chemicals and in-vitro diagnostic reagents[12]. - R&D investment increased by 8.21% to ¥128,735,270.36 in 2022, while the proportion of R&D investment to operating revenue decreased to 2.08% from 2.21%[78]. - The company completed four R&D projects that achieved patent certification, resulting in capitalized R&D investments of ¥48,147,847.72, a 405.09% increase from the previous year[78]. - The company is developing high-purity environmentally friendly potassium peroxymonosulfate as part of its new product strategy[78]. - The company has established partnerships with various research institutions to foster innovation in polymer materials[138]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 25% increase in market share in the region by 2025[12]. - The management has provided a performance guidance of 10-15% revenue growth for 2023, driven by new product launches and market expansion efforts[12]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[12]. - The company aims to expand its production scale and market share by focusing on new applications in electronic chemicals and composite reagents for the semiconductor and new energy materials industries[105]. Operational Efficiency and Challenges - The company is facing risks including macroeconomic downturns and environmental compliance, which could impact future performance[3]. - The company implemented a series of management measures to enhance operational efficiency, including a procurement team rotation system and inventory management strategies[58]. - The company is actively pursuing green and low-carbon production methods, aligning with national energy-saving policies[58]. - The company has reported a significant increase in raw material procurement costs, with sodium hydroxide's cost impact on operating expenses at 29.95%, superabsorbent polymer at 10.35%, and glycerol at 31.21%[44]. Governance and Compliance - The company has established a complete and independent financial accounting system, ensuring autonomous financial decision-making[128]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate communication of significant operational matters to investors[121]. - The company conducted a self-examination and strengthened compliance with securities laws following regulatory measures against its controlling shareholders[143]. - The company received a warning letter from the China Securities Regulatory Commission on November 16, 2022, regarding administrative regulatory measures against its chairman and other executives[142]. Environmental Responsibility - The company has implemented measures to ensure that there are no significant defects in non-financial reporting[176]. - The company has achieved a 100% safe disposal rate for hazardous waste, which includes organic solvents and heavy metal-containing residues[187]. - The company has implemented emergency response plans for environmental incidents, including specific plans for wastewater treatment system failures and gas emission system faults[184]. - The company has maintained a 100% compliance rate for environmental impact assessments and "three simultaneous" systems for all construction projects[193]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,268, with 548 in the parent company and 720 in major subsidiaries[158]. - The company emphasizes the importance of talent development and has conducted annual talent pool updates to ensure a skilled workforce[163]. - The company has established an E-learning platform to promote lifelong learning among employees, covering various topics including marketing and leadership[161]. Customer Engagement and Market Presence - User data indicates a 20% increase in the customer base, reaching 50,000 active users by the end of 2022[12]. - The company has established strategic partnerships with key distributors to enhance sales and customer development, aiming for a win-win cooperation[54]. - The company’s membership and certified buyer numbers on its comprehensive chemical platform, Youliao.com, have continued to rise, reflecting its growing market engagement[50].

证券代码：002584 证券简称：西陇科学 公告编号：2023-018 西陇科学股份有限公司 关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 西陇科学股份有限公司（以下简称"公司"）于2022年4月29日在巨潮资讯 网（http://www.cninfo.com.cn/）上披露了《2022年年度报告》及《2022年年 度报告摘要》。 敬请广大投资者积极参与。 西陇科学股份有限公司 董事会 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年5 月11日（星期四）下午15：00至17:00在互动易平台举行2022年度网上业绩说明 会。本次网上业绩说明会将采用网络远程的方式举行，投资者可登陆深圳证券交 易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与 本次说明会。为广泛听取投资者的意见和建议，2023年5月4日起向投资者征集问 题，投资者可以在会议召开前在互动易首页右侧点击"提问预征集"进入通道。 参与方式一：登陆深圳证券交易所互动易平台（http:// ...

证券代码：002584 证券简称：西陇化工 编号：20140901 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国投瑞银 徐炜哲 | | | 人员姓名 | | | | 时间 | 2014 年 9 月 5 日 | 10:00-11：30 | | 地点 | 广州公司 501 会议室 | | | 上市公司接待人 | 邬军晖 | | | 员姓名 | 莫娇 | | | | 第一部分 公司基本情况 | | | | 1 | 、公司的历史、创始人，发展过程简史。 | | | 2 、化学试剂的产业分析； | | | | 第二部分 交流互动 | ...